Microencapsulated Bifidobacterium longum subsp. infantis ATCC 15697 Favorably Modulates Gut Microbiota and Reduces Circulating Endotoxins in F344 Rats

Abstract EN

The gut microbiota is a bacterial bioreactor whose composition is an asset for human health.

However, circulating gut microbiota derived endotoxins cause metabolic endotoxemia, promoting metabolic and liver diseases.

This study investigates the potential of orally delivered microencapsulated Bifidobacterium infantis ATCC 15697 to modulate the gut microbiota and reduce endotoxemia in F344 rats.

The rats were gavaged daily with saline or microencapsulated B.

infantis ATCC 15697.

Following 38 days of supplementation, the treated rats showed a significant (P < 0.05) increase in fecal Bifidobacteria (4.34 ± 0.46 versus 2.45 ± 0.25% of total) and B.

infantis (0.28 ± 0.21 versus 0.52 ± 0.12 % of total) and a significant (P < 0.05) decrease in fecal Enterobacteriaceae (0.80 ± 0.45 versus 2.83 ± 0.63% of total) compared to the saline control.

In addition, supplementation with the probiotic formulation reduced fecal (10.52 ± 0.18 versus 11.29 ± 0.16 EU/mg; P = 0.01) and serum (0.33 ± 0.015 versus 0.30 ± 0.015 EU/mL; P = 0.25) endotoxins.

Thus, microencapsulated B.

infantis ATCC 15697 modulates the gut microbiota and reduces colonic and serum endotoxins.

Future preclinical studies should investigate the potential of the novel probiotic formulation in metabolic and liver diseases.